View all the latest information in lymphoma and CLL, arranged by trials and clinical studies. Listed below are recently added trial updates.
Outpatient administration of liso-cel: Preliminary results from the OUTREACH study
Due to concerns regarding adverse events (AEs), chimeric antigen receptor (CAR) T-cell therapies are predominantly...
Liso-cel treatment in the outpatient setting
During the American Society of Clinical Oncology (ASCO) Virtual Meeting 2020, Carlos Bachier presented the results of a study evaluating the safety and...
Duvelisib receives a positive opinion from the EMA CHMP for the treatment of R/R CLL and refractory FL
On March 25, 2021, it was announced that duvelisib received a positive opinion from the European...
Results from the phase III DUO trial on duvelisib for relapsed/refractory CLL/SLL
This sphase III trial demonstrated that duvelisib treatment in R/R CLL/SLL patients results in significantly longer...
Real-world outcomes in Germany with standard-of-care axi-cel and tisa-cel for large B-cell lymphoma
Following promising results in clinical trials, the CD19-targeted chimeric antigen receptor (CAR)...
Japanese approval of axicabtagene ciloleucel for the treatment of R/R large B-cell lymphomas
On January 22, 2021, it was announced that the Japanese Ministry of Health, Labour and Welfare approved the...
FDA biologics license application of ublituximab plus umbralisib for the treatment of CLL
On March 29, 2021, it was announced that a biologics license application (BLA) was submitted to the U.S. Food...
Umbralisib and ublituximab combination is superior to current standard of care for patients with untreated, relapsed, or refractory CLL
The synergistic activity of umbralisib, a dual inhibitor of...
a
AATT
ADVL0912
AETHERA
AHL 2011
AIM
ALCANZA
ALEXANDER
ALLIANCE
Alliance A041202
ALPHA
ASCEND
ASPEN
AUGMENT
b
BELIEF
BELINDA
BLAST
BRIGHT
c
CALGB-50303
CALGB-50403
CALGB-50901
CALM
CAPTIVATE
CAVALLI
CC-122-NHL-001
CheckMate 205
CHEMO-T
CHRONOS-3
CITADEL-101
CLARITY
CLL10
CLL12
CLL14
CLL2-GIVe
CLL8
CLOVER-1
COMPLEMENT A+B
CORAL
d
DAWN
DSHNHL 2006-1B/ACT-2
DSHNHL R3
DUO
DURABILITY
DYNAMO
e
E1412
E1912
ECHELON-1
ECHELON-2
ELARA
ELEVATE-RR
ELEVATE-TN
ELIANA
EMBOLDEN
f
FIL_FOLL12
FLASH
FLYER
FORERUNNER
g
GADOLIN
GALEN
GALLIUM
GATHER
GO29365
GO29781
GOYA
h
HD12
HELIOS
HO105
HO130
HO75
i
IELSG32
IELSG36
iLLUMINATE
iNNOVATE
j
JCOG0203
JULIET
k
KEYNOTE-013
KEYNOTE-087
KEYNOTE-170
KEYNOTE-204
l
L-MIND
LNH-Pro-05
LOTIS 2
LUMIERE
LYM-3002
LyMa101
LYMRIT-37-01
m
MabCute
MAGNIFY
MAINTAIN
MARIETTA
MAVORIC
MURANO
n
NCT00466531
NCT00848926
NCT01865617
NCT02260804
NCT02343120
NCT02362997
NCT02535247
NCT02730299
NCT02756897
NCT03206970
o
OAsIs
ORIENT-1
p
PALL
PARMA
PETReA
PHILEMON
PILOT
PIVOTAL
PRECIS
PRIMA
PRIMO
r
RAY
RE-MIND
REFLECTIONS B3281006
RELEVANCE
RELY-30
REMARC
REMoDL-B
RESONATE
RESONATE-2
ROBUST
ROMULUS
s
SABRINA
SADAL
SCHOLAR-1
SEQUOIA
Smart Start
SWOG-9704
t
T-Cell Project
TRANSCEND WORLD
TRANSCEND-CLL-004
TRANSCEND-NHL-001
TRANSCEND-OUTREACH-007
TRANSFORM
Transplant BRaVE
u
UNITY-CLL
UNITY-NHL
v
VIsion/HO141
z
ZUMA-1
ZUMA-12
ZUMA-2
ZUMA-5
ZUMA-7